Pharma Industry News

Stalicla completes phase 1b trials into precision medicine for autism spectrum disorder

STP1 has demonstrated good safety and tolerability profiles, while also showing positive results for neurological functionOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]